ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Onesource Q4 FY26 shows strong sequential recovery driven by semaglutide drug-device combination launches, although annual profits were dragged down by prior delays and exceptional items.
Onesource Specialty Pharma appointed B S R & Co. LLP as Statutory Auditor for five years. The firm serves several major listed companies in the pharma sector.
OneSource reported FY26 revenue of ₹1,421.60 Crore with strong Q4 recovery. Management reaffirmed its FY28 guidance of $400 million organic revenue.
OneSource Specialty Pharma decided not to pursue its proposed merger scheme with SteriScience facilities. The company plans to revisit the transaction following FY28 guidance delivery.
OneSource Specialty Pharma allotted 3,150 equity shares under its ESOP 2021 scheme at INR 278 per share. The allotment slightly increases the company's paid-up capital.
Prateek Gupta resigned as SVP & Head – Technical Development at OneSource Specialty Pharma effective May 13, 2026. This senior management exit follows SEBI regulatory disclosure requirements.
OneSource Specialty Pharma Ltd reported revenue from operations of ₹428.2 Cr (+0.5% YoY) and net profit of ₹4.6 Cr (-95.3% YoY) for Q4 FY26.
OneSource Specialty Pharma Limited reported audited financial results for the year ended March 2026. The board also appointed B S R & Co LLP as auditors.
OneSource Specialty Pharma scheduled a board meeting for May 13, 2026, to approve audited annual financial results. The trading window remains closed until 48 hours post-announcement.
OneSource Specialty Pharma's partner, Orbicular, received Health Canada approval for a generic version of Ozempic (semaglutide). This marks the second generic semaglutide approval in Canada, the world's second-largest market for the drug. OneSource will support commercial supply from its FDA-approved Bengaluru facility, strengthening its global CDMO position in complex injectables.
OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, received Health Canada approval for its generic Semaglutide injection (Ozempic® generic). OneSource will serve as the CDMO partner providing scale-up and commercial manufacturing from its US-FDA approved Bengaluru facility. This regulatory milestone strengthens the partnership and leverages OneSource's specialty manufacturing capabilities.
OneSource Specialty Pharma Limited received an EU GMP Certificate for its Sterile Product Division in Bangalore from German authorities. The certification follows an October 2025 inspection and covers aseptic liquids, secondary packing, and quality control. This approval complements existing US-FDA, Health Canada, ANVISA, and TGA clearances, strengthening the facility's global sterile manufacturing capabilities.
OneSource Specialty Pharma's partner, Orbicular Pharmaceutical Technologies, received tentative U.S. FDA approval for a generic version of Ozempic (Semaglutide Injection). OneSource served as the CDMO partner providing end-to-end manufacturing from its Bangalore facility. This milestone validates OneSource's specialized manufacturing capabilities for complex peptides and injectables.
OneSource Specialty Pharma Limited received the renewal of EU-GMP certification for its flagship Unit II manufacturing facility in Bengaluru. The certification follows a successful inspection by European regulatory authorities. This renewal validates the site's capabilities in biologics drug-substance and sterile injectable manufacturing for the European market.
OneSource Specialty Pharma Limited received an ESG Rating of '73' (Category: Leader) from NSE Sustainability Ratings & Analytics Limited for FY25. The rating was independently assigned based on publicly available information. This recognition highlights the company's commitment to Environmental, Social, and Governance standards.
OneSource Specialty Pharma Ltd reported a net loss of ₹88.7 Cr for Q3 FY26.
Onesource Specialty Pharma Limited allotted 21,450 equity shares on April 9, 2026, following the exercise of options under its ESOP/ESPS scheme. Consequently, the company's paid-up share capital increased from 114,621,201 to 114,642,651 shares. This routine allotment reflects the execution of employee stock benefits.
OneSource Specialty Pharma Limited allotted 21,450 equity shares valued at approximately ₹0.60 Crore under its ESOP 2021 scheme. This allotment follows the exercise of vested options by employees. Consequently, the company's paid-up share capital has increased to ₹11,46,42,651.